Business Development

Why Partner with Juno

Our indepth understanding of the Australian and New Zealand complex hospital market gives us the freedom to explore localised solutions.

It’s our expertise in identifying, sourcing, developing, licensing and launching molecules and our collaborative approach to our partnerships that gives us our competitive edge.

Our Locations

To date, Juno has partnered with over 30 companies worldwide

LATEST BUSINESS NEWS

Juno Launches New Range of Polypropylene Pre-Filled Syringes

Juno is pleased to announce the launch of their new range of polypropylene pre-filled syringes, supplied by Aguettant, a leading French manufacturer of injectable medicines.

Partner With Us

We have built our reputation on the supply of products that meet the previously un-met, unique needs of hospitals and health care specialists.

When businesses partner with Juno, they enter a relationship based on trust and close collaboration. Proudly privately owned, our team of highly experienced professionals are innovative thinkers who work closely with our partners to continually challenge and evolve our portfolio offering.

For more information on partnerning with us, get in touch.

Our areas of focus and types of projects we work on are below:

Hospital

Generic sterile injectable medicines across a range of therapeutic areas

Complex

Complex molecules such as biosimilars as well as products that are challenging to source, develop or manufacture

Specialty

Proprietary brands in-licensed from our partners

Standard Generics

Small molecule generics delivered in standard presentations – chemical molecules that are easily replicated and developed.

Value Added Generics

Improved formulation, new presentations, improved user experience.

We research what products are currently in market, assessing how they’re used before we innovate to improve them for healthcare specialists and their patients.

Difficult to Develop

Complex peptides, sustained release – products that other companies aren’t developing because they’re too challenging.

Biosimilars

Very complex, large molecules that are difficult to develop and launch. The biosimilar market is at the forefront of drug innovation and development.

Proprietary Brands

Branded products in-licenced from partners, generally for the hospital market and often patent protected.